Neurocrine Biosciences (NBIX) EBT Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 21.00% |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.19% |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 3.60% |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -29.91% |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 10.08% |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 39.40% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | -26.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.08% |
| Mar 31, 2026 | 63.73% |
| Dec 31, 2025 | 26.63% |
| Sep 30, 2025 | 43.91% |
| Jun 30, 2025 | 106.81% |
| Mar 31, 2025 | -11.77% |
| Dec 31, 2024 | 139.76% |
| Sep 30, 2024 | 84.10% |
| Jun 30, 2024 | 19.69% |
| Mar 31, 2024 | 8.25% |
| Dec 31, 2023 | 68.13% |
| Sep 30, 2023 | 59.06% |
| Jun 30, 2023 | 13.48% |
| Mar 31, 2023 | -66.98% |
| Dec 31, 2022 | 45.09% |
| Sep 30, 2022 | 18.79% |
| Jun 30, 2022 | -34.76% |
| Mar 31, 2022 | 30.23% |
| Dec 31, 2021 | -39.85% |
| Sep 30, 2021 | -15.62% |